The Medicine Company's cangrelor for the reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention
Read MoreAPR 15 CRDAC
The Medicine Company's cangrelor for the reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention
Read MoreAPR 15 CRDAC
The Medicine Company's cangrelor for the reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention
Read MoreAPR 15 CRDAC
The Medicine Company's cangrelor for the reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention
Read MoreOCT 30 CRDAC
Daiichi Sankyo's edoxaban to prevent stroke and systemic embolism in patients with atrial fibrillation
Read MoreOCT 30 CRDAC
Daiichi Sankyo's edoxaban to prevent stroke and systemic embolism in patients with atrial fibrillation
Read MoreOCT 30 CRDAC
Edoxaban tablets, by Daiichi Sankyo, Inc., for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
Read MoreSEP 10 CRDAC
Utility of a Fixed-Combination Drug Containing an Anti-Hypertensive, Aspirin, and a Statin
Read MoreSEP 12 EMDAC
Natpara by NPS Pharmaceuticals for Hypoparathyroidism
Read MoreSEP 9 CRDAC
Forest’s Nebivolol/Valsartan Fixed-Combination Tablets for Hypertension
Read MoreSEP 10 CRDAC
Utility of a Fixed-Combination Drug Containing an Anti-Hypertensive, Aspirin, and a Statin
Read MoreSEP 9 CRDAC
Forest’s Nebivolol/Valsartan Fixed-Combination Tablets for Hypertension
Read MoreSEP 9 CRDAC
Fixed drug combinations of nebivolol/valsartan by Forest Laboratories for hypertension
Read MoreSEP 9 CRDAC
Forest's (Now Actavis') nebivolol/valsartan for hypertension
Read MoreSEP 10 CRDAC
Fixed-combination of an anti-hypertensive drug, aspirin and a statin
Read More